Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

NCT07520214 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ENROLLING_BY_INVITATION

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Glioblastom WHO Grade 4

Interventions

BIOLOGICAL: mRNA vaccine: GV-907、GV-108

Sponsor

Beijing Neurosurgical Institute